Among the CSC-targeting strategies explored in lung cancer to date, genetic knockdown or pharmacological inhibition of ALDH1 has been shown to attenuate the proliferative and migratory capabilities of NSCLC cells [88]. Here, ALDH1A1 is linked to non-small cell lung carcinoma.